Enhancement Pattern Mapping for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Overview

Journal J Hepatocell Carcinoma

Date 2024 Mar 25

PMID 38525156

Authors

Newsha Nikzad

David Thomas Fuentes

Millicent Roach

Tasadduk Chowdhury

Matthew Cagley

Mohamed Badawy

Ahmed Elkhesen

Manal Hassan

Khaled M Elsayes

Laura Beretta

Eugene Jon Koay

Prasun Kumar Jalal

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Limited methods exist to accurately characterize the risk of malignant progression of liver lesions. Enhancement pattern mapping (EPM) measures voxel-based root mean square deviation (RMSD) of parenchyma and the contrast-to-noise (CNR) ratio enhances in malignant lesions. This study investigates the utilization of EPM to differentiate between HCC versus cirrhotic parenchyma with and without benign lesions.

Methods: Patients with cirrhosis undergoing MRI surveillance were studied prospectively. Cases (n=48) were defined as patients with LI-RADS 3 and 4 lesions who developed HCC during surveillance. Controls (n=99) were patients with and without LI-RADS 3 and 4 lesions who did not develop HCC. Manual and automated EPM signals of liver parenchyma between cases and controls were quantitatively validated on an independent patient set using cross validation with manual methods avoiding parenchyma with artifacts or blood vessels.

Results: With manual EPM, RMSD of 0.37 was identified as a cutoff for distinguishing lesions that progress to HCC from background parenchyma with and without lesions on pre-diagnostic scans (median time interval 6.8 months) with an area under the curve (AUC) of 0.83 (CI: 0.73-0.94) and a sensitivity, specificity, and accuracy of 0.65, 0.97, and 0.89, respectively. At the time of diagnostic scans, a sensitivity, specificity, and accuracy of 0.79, 0.93, and 0.88 were achieved with manual EPM with an AUC of 0.89 (CI: 0.82-0.96). EPM RMSD signals of background parenchyma that did not progress to HCC in cases and controls were similar (case EPM: 0.22 ± 0.08, control EPM: 0.22 ± 0.09, p=0.8). Automated EPM produced similar quantitative results and performance.

Conclusion: With manual EPM, a cutoff of 0.37 identifies quantifiable differences between HCC cases and controls approximately six months prior to diagnosis of HCC with an accuracy of 89%.

References

Chernyak V, Fowler K, Kamaya A, Kielar A, Elsayes K, Bashir M . Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018; 289(3):816-830. PMC: 6677371. DOI: 10.1148/radiol.2018181494. View

Simmons O, Fetzer D, Yokoo T, Marrero J, Yopp A, Kono Y . Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2016; 45(1):169-177. PMC: 7207219. DOI: 10.1111/apt.13841. View

Kim H, An J, Park J, Park S, Lim Y, Lee E . Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. Hepatology. 2018; 69(4):1599-1613. DOI: 10.1002/hep.30330. View

Lee Y, Wang J, Zhu Y, Agopian V, Tseng H, Yang J . Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken). 2021; 17(6):409-413. PMC: 8340355. DOI: 10.1002/cld.1075. View

Yamashita R, Mittendorf A, Zhu Z, Fowler K, Santillan C, Sirlin C . Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. Abdom Radiol (NY). 2019; 45(1):24-35. PMC: 6946904. DOI: 10.1007/s00261-019-02306-7. View

Goldberg D, Taddei T, Serper M, Mehta R, Dieperink E, Aytaman A . Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2016; 65(3):864-874. DOI: 10.1002/hep.28765. View

Hamm C, Wang C, Savic L, Ferrante M, Schobert I, Schlachter T . Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. Eur Radiol. 2019; 29(7):3338-3347. PMC: 7251621. DOI: 10.1007/s00330-019-06205-9. View

Hassett M, Yopp A, Singal A . Surveillance for hepatocellular carcinoma: how can we do better?. Am J Med Sci. 2013; 346(4):308-13. DOI: 10.1097/MAJ.0b013e31828318ff. View

Morshid A, Elsayes K, Khalaf A, Elmohr M, Yu J, Kaseb A . A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019; 1(5). PMC: 6920060. DOI: 10.1148/ryai.2019180021. View

10.

Yushkevich P, Piven J, Hazlett H, Smith R, Ho S, Gee J . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006; 31(3):1116-28. DOI: 10.1016/j.neuroimage.2006.01.015. View

11.

Wu Y, White G, Cornelius T, Gowdar I, Ansari M, Supanich M . Deep learning LI-RADS grading system based on contrast enhanced multiphase MRI for differentiation between LR-3 and LR-4/LR-5 liver tumors. Ann Transl Med. 2020; 8(11):701. PMC: 7327307. DOI: 10.21037/atm.2019.12.151. View

12.

Mokrane F, Lu L, Vavasseur A, Otal P, Peron J, Luk L . Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. Eur Radiol. 2019; 30(1):558-570. DOI: 10.1007/s00330-019-06347-w. View

13.

Zhang L, Wang J, Tang J, Kong X, Yang J, Zheng F . VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep. 2011; 39(5):5085-93. PMC: 4354771. DOI: 10.1007/s11033-011-1304-2. View

14.

Yasaka K, Akai H, Abe O, Kiryu S . Deep Learning with Convolutional Neural Network for Differentiation of Liver Masses at Dynamic Contrast-enhanced CT: A Preliminary Study. Radiology. 2017; 286(3):887-896. DOI: 10.1148/radiol.2017170706. View

15.

Mahmud N, Hoteit M, Goldberg D . Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation. Liver Transpl. 2020; 26(8):977-988. PMC: 7897468. DOI: 10.1002/lt.25787. View

16.

Singal A, Lampertico P, Nahon P . Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020; 72(2):250-261. PMC: 6986771. DOI: 10.1016/j.jhep.2019.08.025. View

17.

Giannini E, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F . Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?. World J Gastroenterol. 2014; 19(47):8808-21. PMC: 3870532. DOI: 10.3748/wjg.v19.i47.8808. View

18.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

19.

Singal A, Nehra M, Adams-Huet B, Yopp A, Tiro J, Marrero J . Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol. 2013; 108(3):425-32. PMC: 5560895. DOI: 10.1038/ajg.2012.449. View

20.

Park P, Choi G, Zaid M, Elganainy D, Smani D, Tomich J . Enhancement pattern mapping technique for improving contrast-to-noise ratios and detectability of hepatobiliary tumors on multiphase computed tomography. Med Phys. 2019; 47(1):64-74. PMC: 7065272. DOI: 10.1002/mp.13769. View